Smarter Cancer Care
Genomic Health delivers the promise and value of precision medicine
with the Oncotype IQ portfolio of genomic tests.
What's New

NCCN Clinical Practice In Oncology (NCCN Guidelines*) for Breast Cancer

Elevating the 21-Gene (Oncotype DX Breast Recurrence Score) test as the only preferred multigene test to predict chemotherapy benefit

*NCCN and NCCN Guidelines are trademarks of the National Comprehensive Cancer Network. © National Comprehensive Cancer Network, Inc. 2018.  All rights reserved.  Accessed [October 5, 2018].  To view the most recent and complete version of the guideline, go to NCCN.org. NCCN makes no warranties of any kind whatsover regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Real People.
Real Results.
When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.
Healthcare Savings
How much do ineffective cancer treatments cost the healthcare system? In the US alone, Oncotype IQ tests have saved more than $3.5 billion.
Practice Tools

The Eighth Edition AJCC Staging Manual is now effect, and it has changed staging for T1-2 N0 M0 breast cancer patients.

Latest TAILORx Data
The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™